Homodeus Research

Homodeus Research
  • 0.0 (0)
  • Investing

Equity research and market commentary from Homodeus Research.

  1. 1d ago

    Trajan (ASX): Stephen Tomisich on Earnings Recovery, AI & Healthcare

    Can Trajan turn its improving earnings and cash generation into sustained growth? In this episode of the Homodeus Research Podcast, Wei Sim speaks with Trajan Group Holdings (ASX) co-founder, CEO and Managing Director Stephen Tomisich about the company’s start to FY27 and its longer-term role in personalised, preventative healthcare. Stephen discusses the September-quarter trading update, the drivers of Trajan’s earnings recovery, improving cash conversion and debt reduction. He explains how manufacturing consolidation, automation and better utilisation of the company’s global footprint could support further margin improvement. The conversation explores Trajan’s components and consumables business, specialised laboratory robotics and growing adoption of blood microsampling for therapeutic drug monitoring. Stephen also discusses AI, mass spectrometry software and multi-year licensing arrangements with two major pharmaceutical companies to support drug discovery. The episode concludes with investor questions on customer concentration, competitive advantages, acquisition priorities, balance-sheet management and the next three to five years of product development. TOPICS COVERED • FY27 first-quarter trading update and earnings recovery • Cash conversion, working capital and debt reduction • Manufacturing consolidation and long-term margin ambitions • Components and consumables growth • Laboratory robotics and workflow automation • AI and analytical data integrity • Mass spectrometry software and drug discovery • Blood microsampling and therapeutic drug monitoring • Personalised and preventative healthcare • Global customer relationships and competitive advantages • Foreign exchange, tariffs and capital equipment demand • Acquisition strategy and capital allocation • New products and the longer-term growth roadmap

  2. Oct 1

    Advanced Engineered Materials (ASX): Richard Seville & Mick Adams on HPA, AI & Semiconductors

    Can Advanced Engineered Materials (ASX) capitalise on rapidly growing demand for high-purity alumina across semiconductors, AI infrastructure and advanced technology? In this episode of the Homodeus Research Podcast, Executive Chair Richard Seville and CEO & Managing Director Mick Adams discuss AEM's high-purity alumina (HPA) business and its commercial-scale production plant in Cap-Chat, Quebec. Richard and Mick explain why HPA is becoming increasingly important across semiconductors, advanced ceramics, thermal management and synthetic sapphire, and how the growth of AI and data centres is contributing to demand for increasingly high-purity materials. The discussion covers AEM's 4N+ and ultra-low-alpha HPA products, customer qualification process, commercial pipeline, pricing dynamics and the emerging global HPA supply shortage. Management also outlines AEM's competitive cost position, access to low-cost renewable power in Quebec, Rio Tinto feedstock supply, plans to scale production and the longer-term pathway toward 6,000 tonnes of annual capacity. The episode also explores semiconductor demand, geopolitical supply-chain shifts, commercial conversion of AEM's qualification pipeline, customer concentration, capital requirements and the company's pathway toward positive cash flow. TOPICS COVERED • What is high-purity alumina (HPA)? • HPA applications in semiconductors and AI • AEM's Cap-Chat production facility in Quebec • 4N+, 5N and ultra-low-alpha HPA • AI and data-centre demand • Global HPA supply constraints • Customer qualification and commercial conversion • AEM's global cost position • Low-cost renewable power from Hydro-Québec • Rio Tinto feedstock supply • Semiconductor and synthetic sapphire markets • Expansion toward 6,000 tonnes of capacity • Sales growth and customer pipeline • Pathway toward positive cash flow • Investor Q&A

  3. Sep 30

    Neurizon Therapeutics (ASX): Sergio Duchini & Dan O'Connell on NUZ-001, HEALEY Phase 2/3 & ALS

    Neurizon Therapeutics (ASX) is approaching a critical period in the development of NUZ-001 for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). In this episode of the Homodeus Research Podcast, Interim Executive Chair Sergio Duchini and CFO Dan O'Connell discuss the completion of recruitment into Neurizon's Phase 2/3 HEALEY ALS Platform Trial, with 250 participants recruited across the United States. The conversation explores why Neurizon chose the HEALEY platform, the encouraging survival signal observed in the earlier Phase 1 MEND study, the trial's clinical endpoints and extensive biomarker program, and the pathway toward the anticipated 2027 data readout. Sergio and Dan also discuss Neurizon's recently established NIH-funded Expanded Access Program, which is expected to provide NUZ-001 to up to 200 additional ALS patients while generating further clinical and real-world data. The episode also covers the transition to incoming CEO Dr Chris Bremmer, Neurizon's regulatory strategy, orphan drug designations, commercial readiness, funding position and the significant unmet medical need and commercial opportunity in ALS. TOPICS COVERED • Neurizon Therapeutics and NUZ-001 • ALS and motor neuron disease explained • Fully recruited Phase 2/3 HEALEY ALS Platform Trial • Why Neurizon selected the HEALEY platform • Phase 1 MEND study and survival signal • Clinical endpoints and exploratory biomarkers • 2027 clinical data timeline • NIH-funded Expanded Access Program • Additional access for up to 200 ALS patients • Incoming CEO Dr Chris Bremmer • Regulatory strategy and orphan drug designation • Commercial readiness and partnering strategy • ALS market opportunity • Investor Q&A

  4. Sep 29

    Aureka Limited (ASX): James Gurry on Fiddlers Creek, Wedderburn Mill & the Path from Explorer to Producer

    Can Aureka Limited (ASX) transform from a Victorian gold explorer into a producer while continuing to advance its larger growth projects? In this episode of the Homodeus Research Podcast, Managing Director James Gurry discusses Aureka’s proposed acquisition of High Grade Holdings and Core Prospecting, bringing the operating Fiddlers Creek high-grade gold and silver mine and the Wedderburn Gold Processing Mill into the group. James explains how the transaction could accelerate Aureka’s transition into production, the spare processing capacity available at Wedderburn, plans to increase production at Fiddlers Creek, and the pathway toward bringing the Comstock Gold Project back into production. The discussion also covers the larger Irvine Gold Project, capital allocation, drilling priorities, production economics, processing capacity, permitting in Victoria, funding requirements and the key milestones investors should watch as Aureka builds an integrated Victorian gold business. The episode concludes with a live investor Q&A covering margins, mill expansion, production growth, high-grade vein gold, infrastructure advantages and the evolving mining environment in Victoria. TOPICS COVERED - Aureka’s transition from explorer to producer - Fiddlers Creek high-grade gold and silver mine - Wedderburn Gold Processing Mill - Spare processing capacity and mill expansion - Comstock Gold Project pathway to production - Irvine Gold Project growth potential - Capital allocation and funding - Production costs and potential margins - Victorian permitting and mining conditions - Upcoming drilling and resource updates - Live investor Q&A

  5. Sep 25

    RareX (ASX): James Durrant on Copper Porphyry Potential, Rare Earths & Mrima Hill

    Could RareX (ASX) be entering a new phase as exploration at Khaleesi shows signs of a potential copper porphyry system while the company advances its broader rare earths and critical minerals strategy? In this episode of the Homodeus Research Podcast, RareX Managing Director James Durrant discusses the company's three-pillar strategy spanning the advanced Cummins Range project, high-impact exploration at Khaleesi and Piper, and the potentially transformational Mrima Hill opportunity in Kenya through its consortium with Iluka Resources. James explains why recent drilling at Khaleesi has increased RareX's interest in the potential for a copper porphyry system, while also outlining the upcoming exploration program at Piper and the development pathway for Cummins Range. The discussion also explores Mrima Hill's rare earth and niobium potential, RareX's relationship with Iluka Resources, the importance of downstream processing infrastructure such as Eneabba, the company's investment portfolio and funding position, and how geopolitical shifts are reshaping global critical mineral supply chains. The episode concludes with a discussion of RareX's upcoming drilling, assay results, development milestones and the key catalysts investors should watch. TOPICS COVERED - RareX's three-pillar growth strategy - Cummins Range rare earths and critical minerals project - Khaleesi and potential copper porphyry mineralisation - Upcoming exploration at Piper - Mrima Hill rare earths and niobium opportunity - Consortium with Iluka Resources - Eneabba and downstream critical minerals processing - Project development and PFS timelines - RareX's investment portfolio and funding position - Geopolitics and critical mineral supply chains - Upcoming exploration and development catalysts

  6. Sep 21

    Dimerix (ASX: DXB): Nina Webster on DMX200, DMX652 & the Global Kidney Drug Opportunity

    Can Dimerix build a global kidney disease business around two clinical-stage drug candidates? Dimerix (ASX: DXB) Managing Director and CEO Nina Webster joins Homodeus Research to discuss the company’s kidney disease pipeline, led by DMX200 and DMX652. DMX200 is being evaluated as a potential treatment for focal segmental glomerulosclerosis (FSGS) in the fully recruited global Phase 3 ACTION3 trial. Nina explains the trial’s clinical endpoints, the significance of its five international commercial partnerships and the milestones leading to top-line results expected in the first half of 2028. The discussion also explores DMX652, Dimerix’s Phase 2 candidate for acute kidney injury following cardiac surgery, including its clinical development program and upcoming milestones. Nina also addresses funding, orphan drug designation, competition, drug pricing, reimbursement, additional licensing opportunities and the key catalysts investors should be watching. TOPICS COVERED - Dimerix’s two-drug kidney disease pipeline - DMX200 and the Phase 3 ACTION3 trial - FSGS and the global treatment opportunity - Proteinuria and eGFR clinical endpoints - Five international commercial partnerships - Potential indications beyond FSGS - DMX652 and acute kidney injury - Phase 2 development milestones - Orphan drug designation - Competition and complementary treatments - Drug pricing and reimbursement - Funding and capital requirements - Global licensing opportunities - Key investor catalysts through 2028

  7. Sep 17

    Whitefield Investments (ASX:WHF, ASX:WHI): Angus Gluskie on Quant Investing, Monthly Franked Income & 100 Years of InvestingHow does a 100-year-old Australian investment manager combine long-term inve

    How does a 100-year-old Australian investment manager combine long-term investing principles with modern quantitative strategies? In this episode of the Homodeus Research Podcast, Angus Gluskie, Managing Director of Whitefield Investments, discusses how Whitefield has evolved since its founding in 1923 and how quantitative investment techniques now sit alongside the firm's long-term investment philosophy. Angus explains the strategies behind Whitefield Industrials and Whitefield Income, including portfolio construction, monthly franked dividends, the role of earnings cycles, and why Whitefield remains focused on Australian equities. The discussion also explores how Whitefield uses data and AI as tools within its investment process, the benefits of staying fully invested, the role of compounding, and how income-focused equity strategies compare with alternatives such as bonds. The episode concludes with investor Q&A covering proprietary data, portfolio construction, costs, long-term returns and how Whitefield's quantitative models have evolved over time. Topics Covered - Whitefield's 100-year investment history - The shift from traditional to quantitative investing - How Whitefield uses AI - Whitefield Industrials - Whitefield Income - Monthly franked dividends - Earnings-cycle investing - Portfolio construction - Compounding and long-term wealth creation - Australian equities versus bonds - Live investor Q&A

  8. Sep 10

    Clarity Pharmaceuticals (ASX:CU6): Executive Chair Dr Alan Taylor on Phase 3, Co-PSMA & the Future of Prostate Cancer ImagingUntitled episode

    Further Reading & Listening 🎧 GU Cast | Urology Podcast – "Is Copper the new Gold??! Co-PSMA trial in European Urology" https://www.podchaser.com/podcasts/gu-cast-urology-podcast-2221144/episodes/is-copper-the-new-gold-co-psma-292293994 📄 European Urology – Co-PSMA Trial Publication https://doi.org/10.1016/j.eururo.2026.03.001 These resources were referenced during the webinar and provide additional clinical context around the Co-PSMA trial and the development of Cu-64 SAR-bisPSMA. Can Clarity Pharmaceuticals (ASX:CU6) become a global leader in radiopharmaceuticals for prostate cancer? In this episode of the Homodeus Research Podcast, Dr Alan Taylor, Executive Chair of Clarity Pharmaceuticals, discusses the company's differentiated copper-based radiopharmaceutical platform, progress across its Phase 3 clinical programs, and the commercial opportunity for next-generation prostate cancer imaging and therapy. Dr Taylor explains why Clarity chose copper isotopes over conventional imaging agents, the science behind the company's proprietary SAR technology, and how its platform is designed to improve both cancer diagnosis and treatment. The discussion covers the landmark Co-PSMA study, progress across the CLARIFY, AMPLIFY and ACCURACY Phase 3 trials, manufacturing strategy, intellectual property, regulatory pathway, commercialisation plans and the long-term outlook for radiopharmaceuticals in oncology. The episode concludes with an extensive live investor Q&A covering competitive positioning, partnerships, M&A, manufacturing capacity, future pipeline expansion and the key catalysts investors should watch over the coming 12–24 months. Whether you're interested in biotechnology, nuclear medicine, oncology or ASX healthcare companies, this episode provides a comprehensive overview of one of Australia's leading radiopharmaceutical developers. Topics Covered - Introduction to Clarity Pharmaceuticals - Why copper isotopes may outperform existing imaging agents - The science behind the SAR technology platform - Co-PSMA clinical trial results - CLARIFY, AMPLIFY & ACCURACY Phase 3 programs - Commercialisation strategy - Manufacturing and intellectual property - Regulatory pathway and future milestones - Expansion beyond prostate cancer - Live investor Q&A

See All (36)

About

Equity research and market commentary from Homodeus Research.

Information

  • Creator
    Homodeus Research
  • Years Active
    2026
  • Episodes
    36
  • Rating
    Clean
  • Copyright
    © Copyright 2026 Homodeus
  • Show Website
    Homodeus Research